Skip to Content

Alfentanil Pregnancy and Breastfeeding Warnings

Alfentanil is also known as: Alfenta

Alfentanil Pregnancy Warnings

Embryocidal effects have been observed in rats and rabbits given doses 2.5 times the upper human dose for a period of 10 days to over 30 days although these effect could have been due to maternal toxicity (decreased food consumption with increased mortality) following prolonged drug administration. This drug rapidly crosses the placenta and may produce respiratory depression in the neonate. This drug is generally not recommended for use in pregnant women during or immediately prior to labor when other analgesic techniques are more appropriate. As with other narcotics, these effects can be quickly reversed with naloxone. There are no adequate and well controlled studies in pregnant women. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Benefit should outweigh risk AU TGA pregnancy category: C US FDA pregnancy category: Not Assigned Risk Summary: Available data in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage; prolonged use during pregnancy may cause neonatal opioid withdrawal syndrome. Comments: -Neonates exposed to opioid analgesics during labor should be monitored for signs of excess sedation and respiratory depression. -Prolonged maternal use of opioids during pregnancy can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

See references

Alfentanil Breastfeeding Warnings

Epidural or IV use during labor or for a short-time immediately postpartum is not expected to cause adverse effects in breastfed infants. In a study of 9 women who received 50 mcg initially and then 10 mcg as needed during tubal ligation surgery under general anesthesia, drug levels at 4 and 28 hours after last injection were 0.88 ng/mL and negligible, respectively.

Benefit should outweigh risk Excreted into human milk: Yes Comments: -Breastfeeding is not recommended for 24 hours following maternal administration. -Breastfed infants should be monitored for excess sedation and respiratory depression.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  4. "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc, Buffalo Grove, IL.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.